Christophe Rochais

ResearcherID Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 34

Top Venues

Molecules (Basel, Switzerland)

Future medicinal chemistry

Nature communications

Molecular informatics

Université de Caen Normandie

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Université de Caen Normandie

France

Professor :: UFR Santé

Publications

Maxime Mistretta, Mena Cimino, Pascal Campagne, Stevenn Volant, Etienne Kornobis, Olivier Hebert, Christophe Rochais, Patrick Dallemagne, Cédric Lecoutey, Camille Tisnerat, Alban Lepailleur, Yann Ayotte, Steven R LaPlante, Nicolas Gangneux, Monika Záhorszká, Jana Korduláková, Sophie Vichier-Guerre, Frédéric Bonhomme, Laura Pokorny, Marvin Albert, Jean-Yves Tinevez, Giulia Manina
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nature communications 15 (1) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry 16 (11) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry (2024)
Mirjana Antonijevic, Despoina Charou, Audrey Davis, Thomas Curel, Maria Valcarcel, Isbaal Ramos, Patricia Villacé, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais
Development of Pleiotropic TrkB and 5-HT 4 Receptor Ligands as Neuroprotective Agents. Molecules (Basel, Switzerland) 29 (2) (2024)
Mirjana Antonijevic, Patrick Dallemagne, Christophe Rochais
Indirect influence on the BDNF/TrkB receptor signaling pathway via GPCRs, an emerging strategy in the treatment of neurodegenerative disorders. Medicinal research reviews (2024)
Mirjana Antonijevic, Despoina Charou, Audrey Davis, Thomas Curel, Maria Valcarcel, Isbaal Ramos, Patricia Villacé, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais
Development of Pleiotropic TrkB and 5-HT 4 Receptor Ligands as Neuroprotective Agents. Molecules (Basel, Switzerland) 29 (2) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry 16 (11) (2024)
Mirjana Antonijevic, Jana Sopkova-de Oliveira Santos, Patrick Dallemagne, Christophe Rochais
Discovery of a pocket network on the domain 5 of the TrkB receptor - A potential new target in the quest for the new ligands. Molecular informatics (2024)
Maxime Mistretta, Mena Cimino, Pascal Campagne, Stevenn Volant, Etienne Kornobis, Olivier Hebert, Christophe Rochais, Patrick Dallemagne, Cédric Lecoutey, Camille Tisnerat, Alban Lepailleur, Yann Ayotte, Steven R LaPlante, Nicolas Gangneux, Monika Záhorszká, Jana Korduláková, Sophie Vichier-Guerre, Frédéric Bonhomme, Laura Pokorny, Marvin Albert, Jean-Yves Tinevez, Giulia Manina
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nature communications 15 (1) (2024)
Chloé Rémondin, Serge M Mignani, Christophe Rochais, Patrick Dallemagne
Synthesis and interest in medicinal chemistry of β-phenylalanine derivatives (β-PAD): an update (2010-2022). Future medicinal chemistry 16 (11) (2024)
Mirjana Antonijevic, Despoina Charou, Audrey Davis, Thomas Curel, Maria Valcarcel, Isbaal Ramos, Patricia Villacé, Sylvie Claeysen, Patrick Dallemagne, Achille Gravanis, Ioannis Charalampopoulos, Christophe Rochais
Development of Pleiotropic TrkB and 5-HT 4 Receptor Ligands as Neuroprotective Agents. Molecules (Basel, Switzerland) 29 (2) (2024)
Mirjana Antonijevic, Jana Sopkova-de Oliveira Santos, Patrick Dallemagne, Christophe Rochais
Discovery of a pocket network on the domain 5 of the TrkB receptor - A potential new target in the quest for the new ligands. Molecular informatics 43 (8) (2024)
Maxime Mistretta, Mena Cimino, Pascal Campagne, Stevenn Volant, Etienne Kornobis, Olivier Hebert, Christophe Rochais, Patrick Dallemagne, Cédric Lecoutey, Camille Tisnerat, Alban Lepailleur, Yann Ayotte, Steven R LaPlante, Nicolas Gangneux, Monika Záhorszká, Jana Korduláková, Sophie Vichier-Guerre, Frédéric Bonhomme, Laura Pokorny, Marvin Albert, Jean-Yves Tinevez, Giulia Manina
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy. Nature communications 15 (1) (2024)
Thomas Guiselin, Cédric Lecoutey, Christophe Rochais, Patrick Dallemagne
Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer's Disease. Pharmaceutics 15 (10) (2023)
Mirjana Antonijevic, Christophe Rochais, Patrick Dallemagne
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug. Molecules (Basel, Switzerland) 28 (2) (2023)
Mirjana Antonijevic, Christophe Rochais, Patrick Dallemagne
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug. Molecules (Basel, Switzerland) 28 (2) (2023)
Mirjana Antonijevic, Christophe Rochais, Patrick Dallemagne
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug. Molecules (Basel, Switzerland) 28 (2) (2023)
Valentin Travers-Lesage, Serge M Mignani, Patrick Dallemagne, Christophe Rochais
Advances in prodrug design for Alzheimer's disease: the state of the art. Expert opinion on drug discovery 17 (4) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Rim Malek, Alexey Simakov, Audrey Davis, Maciej Maj, Paul J Bernard, Artur Wnorowski, Helene Martin, José Marco-Contelles, Fakher Chabchoub, Patrick Dallemagne, Christophe Rochais, Krzysztof Jozwiak, Lhassane Ismaili
Biginelli Reaction Synthesis of Novel Multitarget-Directed Ligands with Ca 2+ Channel Blocking Ability, Cholinesterase Inhibition, Antioxidant Capacity, and Nrf2 Activation. Molecules (Basel, Switzerland) 28 (1) (2022)
Cédric Lecoutey, Rémi Legay, Audrey Davis, Jana Sopková-de Oliveira Santos, Patrick Dallemagne, Christophe Rochais
Development of Novel Potential Pleiotropic Compounds of Interest in Alzheimer's Disease Treatment through Rigidification Strategy. Molecules (Basel, Switzerland) 26 (9) (2021)
Patrick Dallemagne, Christophe Rochais
5-HT4R modulators: a patent landscape. Pharmaceutical patent analyst 10 (4) (2021)
Jean-Jacques Helesbeux, Laura Carro, Florence O McCarthy, Vânia M Moreira, Francesca Giuntini, Niamh M O'Boyle, Susan E Matthews, Gülşah Bayraktar, Samuel Bertrand, Christophe Rochais, Pascal Marchand
29th Annual GP2A Medicinal Chemistry Conference. Pharmaceuticals (Basel, Switzerland) 14 (12) (2021)
Pauline Zipfel, Christophe Rochais, Kévin Baranger, Santiago Rivera, Patrick Dallemagne
Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and Challenges. Journal of medicinal chemistry 63 (19) (2020)
Christophe Rochais, Cédric Lecoutey, Katia Hamidouche, Patrizia Giannoni, Florence Gaven, Eleazere Cem, Serge Mignani, Kevin Baranger, Thomas Freret, Joël Bockaert, Santiago Rivera, Michel Boulouard, Patrick Dallemagne, Sylvie Claeysen
Donecopride, a Swiss army knife with potential against Alzheimer's disease. British journal of pharmacology 177 (9) (2020)
Basile Chrétien, Jean-Pierre Jourdan, Audrey Davis, Sophie Fedrizzi, Ronan Bureau, Marion Sassier, Christophe Rochais, Joachim Alexandre, Véronique Lelong-Boulouard, Charles Dolladille, Patrick Dallemagne
Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease. British journal of clinical pharmacology 87 (7) (2020)
Caroline Lanthier, Patrick Dallemagne, Cédric Lecoutey, Sylvie Claeysen, Christophe Rochais
Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present). Expert opinion on therapeutic patents 30 (7) (2020)
Benjamin Guieu, Cedric Lecoutey, Rémi Legay, Audrey Davis, Jana Sopkova de Oliveira Santos, Cosimo Damiano Altomare, Marco Catto, Christophe Rochais, Patrick Dallemagne
First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer's Disease. Molecules (Basel, Switzerland) 26 (1) (2020)
François-Xavier Toublet, Cédric Lecoutey, Julien Lalut, Bérénice Hatat, Audrey Davis, Marc Since, Sophie Corvaisier, Thomas Freret, Jana Sopkova de Oliveira Santos, Sylvie Claeysen, Michel Boulouard, Patrick Dallemagne, Christophe Rochais
Inhibiting Acetylcholinesterase to Activate Pleiotropic Prodrugs with Therapeutic Interest in Alzheimer's Disease. Molecules (Basel, Switzerland) 24 (15) (2019)
Patrick Dallemagne, Christophe Rochais
Facing the complexity of Alzheimer's disease. Future medicinal chemistry 12 (3) (2019)
Jean-Pierre Jourdan, Marc Since, Laïla El Kihel, Cédric Lecoutey, Sophie Corvaisier, Rémi Legay, Jana Sopkova-de Oliveira Santos, Thierry Cresteil, Aurélie Malzert-Fréon, Christophe Rochais, Patrick Dallemagne
Benzylphenylpyrrolizinones with Anti-amyloid and Radical Scavenging Effects, Potentially Useful in Alzheimer's Disease Treatment. ChemMedChem 12 (12) (2017)

Christophe Rochais.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Christophe Rochais